Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24348727 | 0.84 | DPP4 (0.63) | ALDH1A1KMT2AMAPK1MEN1KDM4E | |
| SCHEMBL859623 | 0.84 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPK1MEN1KDM4E | |
| SCHEMBL20138279 | 0.84 | KDM4E (0.51) | ALDH1A1KMT2AMAPK1MEN1KDM4E | |
| SCHEMBL859998 | 0.84 | KDM4E (0.65) | ALDH1A1KMT2AMAPK1MEN1KDM4E | |
| SCHEMBL13144236 | 0.81 | KDM4E (0.50) | ALDH1A1KMT2AMAPK1MEN1KDM4E | |
| SCHEMBL21995802 | 0.81 | KMT2A (0.47) | ALDH1A1KMT2AMAPK1MEN1KDM4E | |
| SCHEMBL9689634 | 0.81 | KDM4E (0.53) | ALDH1A1KMT2AMAPK1MEN1KDM4E | |
| SCHEMBL13220757 | 0.81 | KMT2A (0.51) | ALDH1A1KMT2AMAPK1MEN1KDM4E | |
| SCHEMBL15072834 | 0.80 | KDM4E (0.70) | ALDH1A1KMT2AMEN1KDM4ENPSR1 | |
| SCHEMBL10517025 | 0.80 | ALDH1A1 (0.48) | ALDH1A1KMT2AMAPK1MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886848-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | Rutgers, The State University of New Jersey (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20210078998-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| WO-2020112845-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-06-04 | — | — | WO | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9763956-B2 | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy | THE BROAD INSTITUTE, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9763956-B2 | Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy | THE BROAD INSTITUTE, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20150315182-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | ALDH1A1 2674/4885KMT2A 2604/4885MAPK1 2068/4885 |
| US-20210078998-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | ALDH1A1 4044/4885KMT2A 3229/4885MAPK1 526/4885 |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | ALDH1A1 680/4885KMT2A 68/4885MAPK1 1471/4885 |
| US-20150315182-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | BMI1, BRPF3, BAZ2A | ALDH1A1 1803/4885KMT2A 166/4885MAPK1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.